What is new for an old molecule? systematic review and recommendations on the use of resveratrol

PLoS ONE

Volumn 6, Issue 6, 2011, Pages

  Vang, Ole ^a   Ahmad, Nihal ^b   Baile, Clifton A ^c   Baur, Joseph A ^d   Brown, Karen ^e   Csiszar, Anna ^f   Das, Dipak K ^g   Delmas, Dominique ^h   Gottfried, Carmem ⁱ   Lin, Hung Yun ^j   Ma, Qing Yong ^k   Mukhopadhyay, Partha ^l   Nalini, Namasivayam ^m   Pezzuto, John M ⁿ   Richard, Tristan ^o   Shukla, Yogeshwer ^p   Surh, Young Joon ^q   Szekeres, Thomas ^r   Szkudelski, Tomasz ^s   Walle, Thomas ^t   Wu, Joseph M ^u   more..

^a ROSKILDE UNIVERSITY   (Denmark)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c UNIVERSITY OF GEORGIA   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e UNIVERSITY OF LEICESTER   (United Kingdom)

^f UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^g UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^h UNIVERSITÉ DE BOURGOGNE   (France)

ⁱ FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^j ORDWAY RESEARCH INSTITUTE   (United States)

^k THE FIRST AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

^l NATIONAL INSTITUTES OF HEALTH   (United States)

^m ANNAMALAI UNIVERSITY   (India)

ⁿ UNIVERSITY OF HAWAII AT HILO   (United States)

^o UNIVERSITÉ DE BORDEAUX   (France)

^p CSIR INDIAN INSTITUTE OF TOXICOLOGY RESEARCH   (India)

^q Seoul National University   (South Korea)

^r UNIVERSITY OF VIENNA   (Austria)

^s POZNA UNIVERSITY OF LIFE SCIENCES   (Poland)

^t MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^u NEW YORK MEDICAL COLLEGE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CYCLOOXYGENASE 2; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; PLACEBO; RESVERATROL; TUMOR NECROSIS FACTOR ALPHA; STILBENE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BONE DEVELOPMENT; BRAIN INJURY; CANCER INHIBITION; CANCER PREVENTION; CELL PROLIFERATION; COGNITION; COLON CANCER; CONSENSUS DEVELOPMENT; DENMARK; DIARRHEA; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG METABOLISM; DRUG RESEARCH; DRUG SAFETY; DRUG TOLERABILITY; EMBRYO DEVELOPMENT; FETUS DEVELOPMENT; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GROWTH INHIBITION; HEART FAILURE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HORMONAL REGULATION; HUMAN; HYPERTENSION; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; INSULIN SENSITIVITY; ISCHEMIC HEART DISEASE; LONGEVITY; LOOSE FECES; MALIGNANT NEOPLASTIC DISEASE; MAXIMUM PLASMA CONCENTRATION; METABOLIC SYNDROME X; MITOCHONDRIAL PERMEABILITY; NERVE DEGENERATION; NEUROLOGIC DISEASE; NEUROPROTECTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRACTICE GUIDELINE; PROSTATE CANCER; REPRODUCTIVE TOXICITY; REVIEW; RISK REDUCTION; SYSTEMATIC REVIEW; THERAPY EFFECT; TREATMENT INDICATION; XENOBIOTIC METABOLISM;

ANIMALIA;

HUMANS; STILBENES;

EID: 79959261445     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0019881     Document Type: Review

References (145)

1. Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, et al. (1997) Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275: 218-220.
2. Brown VA, Patel KR, Viskaduraki M, Crowell JA, Perloff M, et al. (2010) Repeat Dose Study of the Cancer Chemopreventive Agent Resveratrol in Healthy Volunteers: Safety, Pharmacokinetics and Effect on the Insulin-like Growth Factor Axis. Cancer Res 70: 9003-9011.
3. Patel KR, Brown VA, Jones DJ, Britton RG, Hemingway D, et al. (2010) Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients. Cancer Res 70: 7392-7399.
4. Soleas GJ, Yan J, Goldberg DM, (2001) Ultrasensitive assay for three polyphenols (catechin, quercetin and resveratrol) and their conjugates in biological fluids utilizing gas chromatography with mass selective detection. J Chromatogr B Biomed Sci Appl 757: 161-172.
5. Goldberg DM, Yan J, Soleas GJ, (2003) Absorption of three wine-related polyphenols in three different matrices by healthy subjects. Clin Biochem 36: 79-87.
6. Walle T, Hsieh F, DeLegge MH, Oatis JE, Walle UK, (2004) High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos 32: 1377-1382.
7. Boocock DJ, Patel KR, Faust GE, Normolle DP, Marczylo TH, et al. (2007) Quantitation of trans-resveratrol and detection of its metabolites in human plasma and urine by high performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 848: 182-187.
8. Boocock DJ, Faust GE, Patel KR, Schinas AM, Brown VA, et al. (2007) Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidem Biomark Prev 16: 1246-1252.
9. la Porte C, Voduc N, Zhang G, Seguin I, Tardiff D, et al. (2010) Steady-State pharmacokinetics and tolerability of trans-resveratrol 2000 mg twice daily with food, quercetin and alcohol (ethanol) in healthy human subjects. Clin Pharmacokinet 49: 449-454.
10. Almeida L, Vaz-da-Silva M, Falcao A, Soares E, Costa R, et al. (2009) Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers. Mol Nutr Food Res 53: 7-15.
11. Burkon A, Somoza V, (2008) Quantification of free and protein-bound trans-resveratrol metabolites and identification of trans-resveratrol-C/O-conjugated diglucuronides- two novel resveratrol metabolites in human plasma. Mol Nutr Food Res 52: 549-557.
12. Meng X, Maliakal P, Lu H, Lee MJ, Yang CS, (2004) Urinary and plasma levels of resveratrol and quercetin in humans, mice, and rats after ingestion of pure compounds and grape juice. J Agric Food Chem 52: 935-942.
13. Vitaglione P, Sforza S, Galaverna G, Ghidini C, Caporaso N, et al. (2005) Bioavailability of trans-resveratrol from red wine in humans. Mol Nutr Food Res 49: 495-504.
14. Zamora-Ros R, Urpi-Sarda M, Lamuela-Raventos RM, Estruch R, Vazquez-Agell M, et al. (2006) Diagnostic performance of urinary resveratrol metabolites as a biomarker of moderate wine consumption. Clin Chem 52: 1373-1380.
15. Vaz-da-Silva M, Loureiro AI, Falcao A, Nunes T, Rocha JF, et al. (2008) Effect of food on the pharmacokinetic profile of trans-resveratrol. Int J Clin Pharmacol Ther 46: 564-570.
16. Elliott PJ, Walpole S, Morelli L, Lambert PD, Lunsmann W, et al. (2009) Resveratrol/SRT501. Sirtuin SIRT1 activator, Treatment of type 2 diabetes. Drugs Fut 34: 291-295.
17. Kennedy DO, Wightman EL, Reay JL, Lietz G, Okello EJ, et al. (2010) Effects of resveratrol on cerebral blood flow variables and cognitive performance in humans: a double-blind, placebo-controlled, crossover investigation. Am J Clin Nutr 91: 1590-1597.
18. (2010) Resveratrol trials at ClinicalTrial.gov.
19. Wong RH, Howe PR, Buckley JD, Coates AM, Kunz I, et al. (2010) Acute resveratrol supplementation improves flow-mediated dilatation in overweight/obese individuals with mildly elevated blood pressure. Nutr Metab Cardiovasc Dis DOI:10.1016/j.numecd.2010.03.003.
20. Stervbo U, Vang O, Bonnesen C, (2007) A review of the content of the putative chemopreventive phytoalexin resveratrol in red wine. Food Chem 101: 449-457.
21. Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, et al. (2006) Resveratrol improves health and survival of mice on a high-calorie diet. Nature 444: 337-342.
22. Juan ME, Vinardell MP, Planas JM, (2002) The daily oral administration, of high doses of trans-resveratrol to rats for 28 days is not harmful. J Nutr 132: 257-260.
23. Crowell JA, Korytko PJ, Morrissey RL, Booth TD, Levine BS, (2004) Resveratrol-associated renal toxicity. Toxicol Sci 82: 614-619.
24. Williams LD, Burdock GA, Edwards JA, Beck M, Bausch J, (2009) Safety studies conducted on high-purity trans-resveratrol in experimental animals. Food Chem Toxicol 49: 2170-8221.
25. Hebbar V, Shen GX, Hu R, Kim BR, Chen C, et al. (2005) Toxicogenomics of resveratrol in rat liver. Life Sci 76: 2299-2314.
26. Whitsett TG Jr, Carpenter DM, Lamartiniere CA, (2006) Resveratrol, but not EGCG, in the diet suppresses DMBA-induced mammary cancer in rats. J Carcinog 5: 15.
27. Horn TL, Cwik MJ, Morrissey RL, Kapetanovic I, Crowell JA, et al. (2007) Oncogenicity evaluation of resveratrol in p53(+/-) (p53 knockout) mice. Food Chem Toxicol 45: 55-63.
28. Wong YT, Gruber J, Jenner AM, Ng MP, Ruan R, et al. (2009) Elevation of oxidative-damage biomarkers during aging in F2 hybrid mice: protection by chronic oral intake of resveratrol. Free Radic Biol Med 46: 799-809.
29. Watzl B, Bub A, Pretzer G, Roser S, Barth SW, et al. (2004) Daily moderate amounts of red wine or alcohol have no effect on the immune system of healthy men. Eur J Clin Nutr 58: 40-45.
30. Watzl B, Bub A, Briviba K, Rechkemmer G, (2002) Acute intake of moderate amounts of red wine or alcohol has no effect on the immune system of healthy men. Eur J Nutr 41: 264-270.
31. Vazquez-Agell M, Sacanella E, Tobias E, Monagas M, Antunez E, et al. (2007) Inflammatory markers of atherosclerosis are decreased after moderate consumption of cava (sparkling wine) in men with low cardiovascular risk. J Nutr 137: 2279-2284.
32. Reagan-Shaw S, Nihal M, Ahmad N, (2008) Dose translation from animal to human studies revisited. FASEB J 22: 659-661.
33. Kapadia GJ, Azuine MA, Tokuda H, Takasaki M, Mukainaka T, et al. (2002) Chemopreventive effect of resveratrol, sesamol, sesame oil and sunflower oil in the Epstein-Barr virus early antigen activation assay and the mouse skin two-stage carcinogenesis. Pharmacol Res 45: 499-505.
34. Soleas GJ, Grass L, Josephy PD, Goldberg DM, Diamandis EP, (2002) A comparison of the anticarcinogenic properties of four red wine polyphenols. Clin Biochem 35: 119-124.
35. Yusuf N, Nasti TH, Meleth S, Elmets CA, (2009) Resveratrol enhances cell-mediated immune response to DMBA through TLR4 and prevents DMBA induced cutaneous carcinogenesis. Mol Carcinogen 48: 713-723.
36. Roy P, Kalra N, Prasad S, George J, Shukla Y, (2009) Chemopreventive Potential of Resveratrol in Mouse Skin Tumors Through Regulation of Mitochondrial and PI3K/AKT Signaling Pathways. Pharm Res 26: 211-217.
37. Niles RM, Cook CP, Meadows GG, Fu YM, McLaughlin JL, et al. (2006) Resveratrol is rapidly metabolized in athymic (Nu/Nu) mice and does not inhibit human melanoma xenograft tumor growth. J Nutr 136: 2542-2546.
38. Kowalczyk MC, Kowalczyk P, Tolstykh O, Hanausek M, Walaszek Z, et al. (2010) Synergistic effects of combined phytochemicals and skin cancer prevention in SENCAR mice. Cancer Prev Res 3: 170-178.
39. Provinciali M, Re F, Donnini A, Orlando F, Bartozzi B, et al. (2005) Effect of Resveratrol on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Int J Cancer 115: 36-45.
40. El-Mowafy AM, El-Mesery ME, Salem HA, Al-Gayyar MM, Darweish MM, (2010) Prominent chemopreventive and chemoenhancing effects for resveratrol: unraveling molecular targets and the role of C-reactive protein. Chemotherapy 56: 60-65.
41. Bove K, Lincoln DW, Tsan MF, (2002) Effect of resveratrol on growth of 4T1 breast cancer cells in vitro and in vivo. Biochem Biophys Res Commun 291: 1001-1005.
42. Bhat KPL, Lantvit D, Christov K, Mehta RG, Moon RC, et al. (2001) Estrogenic and antiestrogenic properties of resveratrol in mammary tumor models. Cancer Res 61: 7456-7463.
43. Banerjee S, Bueso-Ramos C, Aggarwal BB, (2002) Suppression of 7,12-dimethylbenz(a)anthracene-induced mammary carcinogenesis in rats by resveratrol: Role of nuclear factor-kappa B, cyclooxygenase 2, and matrix metalloprotease 9. Cancer Res 62: 4945-4954.
44. Sato M, Pei RJ, Yuri T, Danbara N, Nakane Y, et al. (2003) Prepubertal resveratrol exposure accelerates N-methyl-N-nitrosourea-induced mammary carcinoma in female Sprague-Dawley rats. Cancer Lett 202: 137-145.
45. Bishayee A, Dhir N, (2009) Resveratrol-mediated chemoprevention of diethylnitrosamine-initiated hepatocarcinogenesis: inhibition of cell proliferation and induction of apoptosis. Chem Biol Interact 179: 131-144.
46. Asensi M, Medina I, Ortega A, Carretero J, Bano MC, et al. (2002) Inhibition of cancer growth by resveratrol is related to its low bioavailability. Free Radic Biol Med 33: 387-398.
47. Yu L, Sun ZJ, Wu SL, Pan CE, (2003) Effect of resveratrol on cell cycle proteins in murine transplantable liver cancer. World J Gastroenterol 9: 2341-2343.
48. Liu HS, Pan CE, Yang W, Liu XM, (2003) Antitumor and immunomodulatory activity of resveratrol on experimentally implanted tumor of H22 in Balb/c mice. World J Gastroenterol 9: 1474-1476.
49. Woodall CE, Li Y, Liu QH, Wo J, Martin RC, (2009) Chemoprevention of metaplasia initiation and carcinogenic progression to esophageal adenocarcinoma by resveratrol supplementation. Anti Cancer Drug 20: 437-443.
50. Zhou HB, Chen JJ, Wang WX, Cai JT, Du Q, (2005) Anticancer activity of resveratrol on implanted human primary gastric carcinoma cells in nude mice. World J Gastroenterol 11: 280-284.
51. Wyke SM, Russell ST, Tisdale MJ, (2004) Induction of proteasome expression in skeletal muscle is attenuated by inhibitors of NF-kappaB activation. Br J Cancer 91: 1742-1750.
52. Sengottuvelan M, Nalini N, (2006) Dietary supplementation of resveratrol suppresses colonic tumour incidence in 1,2-dimethylhydrazine-treated rats by modulating biotransforming enzymes and aberrant crypt foci development. Br J Nutr 96: 145-153.
53. Tessitore L, Davit A, Sarotto I, Caderni G, (2000) Resveratrol depresses the growth of colorectal aberrant crypt foci by affecting bax and p21(CIP) expression. Carcinogenesis 21: 1619-1622.
54. Kineman BD, Au A, Paiva NL, Kaiser MS, Brummer EC, et al. (2007) Transgenic alfalfa that accumulates piceid (Trans-Resveratrol-3-O-Beta-D-glucopyranoside) requires the presence of beta-glucosidase to inhibit the formation of aberrant crypt foci in the colon of CF-1 mice. Nutr Cancer 58: 66-74.
55. Cui X, Jin Y, Hofseth AB, Pena E, Habiger J, et al. (2010) Resveratrol suppresses colitis and colon cancer associated with colitis. Cancer Prev Res 3: 549-559.
56. Schneider Y, Duranton B, Gosse F, Schleiffer R, Seiler N, et al. (2001) Resveratrol inhibits intestinal tumorigenesis and modulates host-defense-related gene expression in an animal model of human familial adenomatous polyposis. Nutr Cancer 39: 102-107.
57. Ziegler CC, Rainwater L, Whelan J, McEntee MF, (2004) Dietary resveratrol does not affect intestinal tumorigenesis in Apc(Min/+) mice. J Nutr 134: 5-10.
58. Sale S, Tunstall RG, Ruparelia KC, Potter GA, Steward WP, et al. (2005) Comparison of the effects of the chemopreventive agent resveratrol and its synthetic analog trans 3,4,5,4′-tetramethoxystilbene (DMU-212) on adenoma development in the Apc(Min+) mouse and cyclooxygenase-2 in human-derived colon cancer cells. Int J Cancer 115: 194-201.
59. Harper CE, Cook LM, Patel BB, Wang J, Eltoum IA, et al. (2009) Genistein and resveratrol, alone and in combination, suppress prostate cancer in SV-40 tag rats. Prostate 69: 1668-1682.
60. Seeni A, Takahashi S, Takeshita K, Tang M, Sugiura S, et al. (2008) Suppression of prostate cancer growth by resveratrol in the transgenic rat for adenocarcinoma of prostate (TRAP) model. Asian Pac J Cancer Prev 9: 7-14.
61. Narayanan NK, Nargi D, Randolph C, Narayanan BA, (2009) Liposome encapsulation of curcumin and resveratrol in combination reduces prostate cancer incidence in PTEN knockout mice. Int J Cancer 125: 1-8.
62. Wang TT, Hudson TS, Wang TC, Remsberg CM, Davies NM, et al. (2008) Differential effects of resveratrol on androgen-responsive LNCaP human prostate cancer cells in vitro and in vivo. Carcinogenesis 29: 2001-2010.
63. Hecht SS, Kenney PM, Wang M, Trushin N, Agarwal S, et al. (1999) Evaluation of butylated hydroxyanisole, myo-inositol, curcumin, esculetin, resveratrol and lycopene as inhibitors of benzo[a]pyrene plus 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced lung tumorigenesis in A/J mice. Cancer Lett 137: 123-130.
64. Caltagirone S, Rossi C, Poggi A, Ranelletti FO, Natali PG, et al. (2000) Flavonoids apigenin and quercetin inhibit melanoma growth and metastatic potential. Int J Cancer 87: 595-600.
65. Kimura Y, Okuda H, (2001) Resveratrol isolated from Polygonum cuspidatum root prevents tumor growth and metastasis to lung and tumor-induced neovascularization in Lewis lung carcinoma-bearing mice. J Nutr 131: 1844-1849.
66. Berge G, Ovrebo S, Eilertsen E, Haugen A, Mollerup S, (2004) Analysis of resveratrol as a lung cancer chemopreventive agent in A/J mice exposed to benzo[alpha] pyrene. Br J Cancer 91: 1380-1383.
67. Chen Y, Tseng SH, Lai HS, Chen WJ, (2004) Resveratrol-induced cellular apoptosis and cell cycle arrest in neuroblastoma cells and antitumor effects on neuroblastoma in mice. Surgery 136: 57-66.
68. Behbahani J, Thandapilly SJ, Louis XL, Huang Y, Shao Z, et al. (2010) Resveratrol and small artery compliance and remodeling in the spontaneously hypertensive rat. Am J Hypertens 23: 1273-1278.
69. Thandapilly SJ, Wojciechowski P, Behbahani J, Louis XL, Yu L, et al. (2010) Resveratrol prevents the development of pathological cardiac hypertrophy and contractile dysfunction in the SHR without lowering blood pressure. Am J Hypertens 23: 192-196.
70. Chan V, Fenning A, Iyer A, Hoey A, Brown L, (2011) Resveratrol improves cardiovascular function in DOCA-salt hypertensive rats. Curr Pharm Biotechnol 12: 429-436.
71. Yang DL, Zhang HG, Xu YL, Gao YH, Yang XJ, et al. (2010) Resveratrol inhibits right ventricular hypertrophy induced by monocrotaline in rats. Clin Exp Pharmacol Physiol 37: 150-155.
72. Csiszar A, Labinskyy N, Olson S, Pinto JT, Gupte S, et al. (2009) Resveratrol prevents monocrotaline-induced pulmonary hypertension in rats. Hypertension 54: 668-675.
73. Rivera L, Moron R, Zarzuelo A, Galisteo M, (2009) Long-term resveratrol administration reduces metabolic disturbances and lowers blood pressure in obese Zucker rats. Biochem Pharmacol 77: 1053-1063.
74. Sutra T, Oiry C, zay-Milhau J, Youl E, Magous R, et al. (2008) Preventive effects of nutritional doses of polyphenolic molecules on cardiac fibrosis associated with metabolic syndrome: Involvement of osteopontin and oxidative stress. J Agric Food Chem 56: 11683-11687.
75. Miatello R, Vazquez M, Renna N, Cruzado M, Zumino AP, et al. (2005) Chronic administration of resveratrol prevents biochemical cardiovascular changes in fructose-fed rats. Am J Hypertens 18: 864-870.
76. Aubin MC, Lajoie C, Clement R, Gosselin H, Calderone A, et al. (2008) Female rats fed a high-fat diet were associated with vascular dysfunction and cardiac fibrosis in the absence of overt obesity and hyperlipidemia: therapeutic potential of resveratrol. J Pharmacol Exp Ther 325: 961-968.
77. Chen YR, Yi FF, Li XY, Wang CY, Chen L, et al. (2008) Resveratrol attenuates ventricular arrhythmias and improves the long-term survival in rats with myocardial infarction. Cardiovasc Drugs Ther 22: 479-485.
78. Lin JF, Lin SM, Chih CL, Nien MW, Su HH, et al. (2008) Resveratrol reduces infarct size and improves ventricular function after myocardial ischemia in rats. Life Sci 83: 313-317.
79. Burstein B, Maguy A, Clement R, Gosselin H, Poulin F, et al. (2007) Effects of resveratrol (trans-3,5,4′-trihydroxystilbene) treatment on cardiac remodeling following myocardial infarction. J Pharmacol Exp Ther 323: 916-923.
80. Fukuda S, Kaga S, Zhan L, Bagchi D, Das DK, et al. (2006) Resveratrol ameliorates myocardial damage by inducing vascular endothelial growth factor-angiogenesis and tyrosine kinase receptor Flk-1. Cell Biochem Biophys 44: 43-49.
81. Wojciechowski P, Juric D, Louis XL, Thandapilly SJ, Yu L, et al. (2010) Resveratrol arrests and regresses the development of pressure overload- but not volume overload-induced cardiac hypertrophy in rats. J Nutr 140: 962-968.
82. Saleh MC, Connell BJ, Saleh TM, (2010) Resveratrol preconditioning induces cellular stress proteins and is mediated via NMDA and estrogen receptors. Neuroscience 166: 445-454.
83. Huang JP, Huang SS, Deng JY, Chang CC, Day YJ, et al. (2010) Insulin and resveratrol act synergistically, preventing cardiac dysfunction in diabetes, but the advantage of resveratrol in diabetics with acute heart attack is antagonized by insulin. Free Radic Biol Med 49: 1710-1721.
84. Lekli I, Szabo G, Juhasz B, Das S, Das M, et al. (2007) Protective mechanisms of resveratrol against ischemia/reperfusion-induced damage in hearts obtained from Zucker obese rats: the role of GLUT-4 and endothelin. Am J Physiol Heart Circ Physiol 294: H859-H866.
85. Thirunavukkarasu M, Penumathsa SV, Koneru S, Juhasz B, Zhan L, et al. (2007) Resveratrol alleviates cardiac dysfunction in streptozotocin-induced diabetes: Role of nitric oxide, thioredoxin, and heme oxygenase. Free Radic Biol Med 43: 720-729.
86. Dudley J, Das S, Mukherjee S, Das DK, (2009) Resveratrol, a unique phytoalexin present in red wine, delivers either survival signal or death signal to the ischemic myocardium depending on dose. J Nutr Biochem 20: 443-452.
87. Das S, Tosaki A, Bagchi D, Maulik N, Das DK, (2006) Potentiation of a survival signal in the ischemic heart by resveratrol through p38 mitogen-activated protein kinase/mitogen- and stress-activated protein kinase 1/cAMP response element-binding protein signaling. J Pharmacol Exp Ther 317: 980-988.
88. Robich MP, Osipov RM, Nezafat R, Feng J, Clements RT, et al. (2010) Resveratrol improves myocardial perfusion in a swine model of hypercholesterolemia and chronic myocardial ischemia. Circulation 122: S142-S149.
89. Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, et al. (2006) Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 127: 1109-1122.
90. Dal-Pan A, Blanc S, Aujard F, (2010) Resveratrol suppresses body mass gain in a seasonal non-human primate model of obesity. BMC Physiol 10: 11.
91. Macarulla MT, Alberdi G, Gomez S, Tueros I, Bald C, et al. (2009) Effects of different doses of resveratrol on body fat and serum parameters in rats fed a hypercaloric diet. J Physiol Biochem 65: 369-376.
92. Shang J, Chen LL, Xiao FX, Sun H, Ding HC, et al. (2008) Resveratrol improves non-alcoholic fatty liver disease by activating AMPactivated protein kinase. Acta Pharmacol Sin 29: 698-706.
93. Bujanda L, Hijona E, Larzabal M, Beraza M, Aldazabal P, et al. (2008) Resveratrol inhibits nonalcoholic fatty liver disease in rats. BMC Gastroenterol 8: 40.
94. Palsamy P, Subramanian S, (2008) Resveratrol, a natural phytoalexin, normalizes hyperglycemia in streptozotocin-nicotinamide induced experimental diabetic rats. Biomed Pharmacother 62: 598-605.
95. Gonzalez-Rodriguez A, Mas Gutierrez JA, Sanz-Gonzalez S, Ros M, Burks DJ, et al. (2010) Inhibition of PTP1B restores IRS1-mediated hepatic insulin signaling in IRS2-deficient mice. Diabetes 59: 588-599.
96. Um JH, Park SJ, Kang H, Yang S, Foretz M, et al. (2010) AMP-activated protein kinase-deficient mice are resistant to the metabolic effects of resveratrol. Diabetes 59: 554-563.
97. Ramadori G, Gautron L, Fujikawa T, Vianna CR, Elmquist JK, et al. (2009) Central administration of resveratrol improves diet-induced diabetes. Endocrinology 150: 5326-5333.
98. Milne JC, Lambert PD, Schenk S, Carney DP, Smith JJ, et al. (2007) Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 450: 712-716.
99. Rocha KK, Souza GA, Ebaid GX, Seiva FR, Cataneo AC, et al. (2009) Resveratrol toxicity: effects on risk factors for atherosclerosis and hepatic oxidative stress in standard and high-fat diets. Food Chem Toxicol 47: 1362-1367.
100. Kim YH, Kim YS, Kang SS, Cho GJ, Choi WS, (2010) Resveratrol inhibits neuronal apoptosis and elevated Ca2+/calmodulin-dependent protein kinase II activity in diabetic mouse retina. Diabetes 59: 1825-1835.
101. Akar F, Pektas MB, Tufan C, Soylemez S, Sepici A, et al. (2011) Resveratrol shows vasoprotective effect reducing oxidative stress without affecting metabolic disturbances in insulin-dependent diabetes of rabbits. Cardiovasc Drugs Ther DOI:10.1007/s10557-010-6255-7.
102. Kiziltepe U, Turan NN, Han U, Ulus AT, Akar F, (2004) Resveratrol, a red wine polyphenol, protects spinal cord from ischemia-reperfusion injury. J Vasc Surg 40: 138-145.
103. Yang YB, Piao YJ, (2003) Effects of resveratrol on secondary damages after acute spinal cord injury in rats. Acta Pharmacol Sin 24: 703-710.
104. Sinha K, Chaudhary G, Gupta YK, (2002) Protective effect of resveratrol against oxidative stress in middle cerebral artery occlusion model of stroke in rats. Life Sci 71: 655-665.
105. Ates O, Cayli SR, Yucel N, Altinoz E, Kocak A, et al. (2007) Central nervous system protection by resveratrol in streptozotocin-induced diabetic rats. J Clin Neurosci 14: 256-260.
106. Mokni M, Elkahoui S, Limam F, Amri M, Aouani E, (2007) Effect of resveratrol on antioxidant enzyme activities in the brain of healthy rat. Neurochem Res 32: 981-987.
107. Robb EL, Winkelmolen L, Visanji N, Brotchie J, Stuart JA, (2008) Dietary resveratrol administration increases MnSOD expression and activity in mouse brain. Biochem Biophys Res Commun 372: 254-259.
108. Ates O, Cayli S, Altinoz E, Gurses I, Yucel N, et al. (2007) Neuroprotection by resveratrol against traumatic brain injury in rats. Mol Cell Biochem 294: 137-144.
109. Wang Q, Yu S, Simonyi A, Rottinghaus G, Sun GY, et al. (2004) Resveratrol protects against neurotoxicity induced by kainic acid. Neurochem Res 29: 2105-2112.
110. Tsai SK, Hung LM, Fu YT, Cheng H, Nien MW, et al. (2007) Resveratrol neuroprotective effects during focal cerebral ischemia injury via nitric oxide mechanism in rats. J Vasc Surg 46: 346-353.
111. Karuppagounder SS, Pinto JT, Xu H, Chen LH, Beal MF, et al. (2009) Dietary supplementation with resveratrol reduces plaque pathology in a transgenic model of Alzheimer's disease. Neurochem Int 54: 111-118.
112. Ates O, Cayli S, Altinoz E, Gurses I, Yucel N, et al. (2006) Effects of resveratrol and methylprednisolone on biochemical, neurobehavioral and histopathological recovery after experimental spinal cord injury. Acta Pharmacol Sin 27: 1317-1325.
113. Yousuf S, Atif F, Ahmad M, Hoda N, Ishrat T, et al. (2009) Resveratrol exerts its neuroprotective effect by modulating mitochondrial dysfunctions and associated cell death during cerebral ischemia. Brain Res 1250: 242-253.
114. Lu KT, Chiou RY, Chen LG, Chen MH, Tseng WT, et al. (2006) Neuroprotective effects of resveratrol on cerebral ischemia-induced neuron loss mediated by free radical scavenging and cerebral blood flow elevation. J Agric Food Chem 54: 3126-3131.
115. Sakata Y, Zhuang H, Kwansa H, Koehler RC, Dore S, (2010) Resveratrol protects against experimental stroke: Putative neuroprotective role of heme oxygenase 1. Exp Neurol 224: 325-329.
116. Della-Morte D, Dave KR, Defazio RA, Bao YC, Raval AP, et al. (2009) Resveratrol pretreatment protects rat brain from cerebral ischemic damage via a sirtuin 1 - uncoupling protein 2 pathway. Neuroscience 159: 993-1002.
117. Wu Z, Xu Q, Zhang L, Kong D, Ma R, et al. (2009) Protective effect of resveratrol against kainate-induced temporal lobe epilepsy in rats. Neurochem Res 34: 1393-1400.
118. Lu KT, Ko MC, Chen BY, Huang JC, Hsieh CW, et al. (2008) Neuroprotective Effects of Resveratrol on MPTP-Induced Neuron Loss Mediated by Free Radical Scavenging. J Agric Food Chem 56: 6910-6913.
119. Sonmez U, Sonmez A, Erbil G, Tekmen I, Baykara B, (2007) Neuroprotective effects of resveratrol against traumatic brain injury in immature rats. Neurosci Lett 420: 133-137.
120. Singleton RH, Yan HQ, Fellows-Mayle W, Dixon CE, (2010) Resveratrol attenuates behavioral impairments and reduces cortical and hippocampal loss in a rat controlled cortical impact model of traumatic brain injury. J Neurotrauma 27: 1091-1099.
121. Khan MM, Ahmad A, Ishrat T, Khan MB, Hoda MN, et al. (2010) Resveratrol attenuates 6-hydroxydopamine-induced oxidative damage and dopamine depletion in rat model of Parkinson's disease. Brain Res 1328: 139-151.
122. Binienda ZK, Beaudoin MA, Gough B, Ali SF, Virmani A, (2010) Assessment of 3-nitropropionic acid-evoked peripheral neuropathy in rats: neuroprotective effects of acetyl-L-carnitine and resveratrol. Neurosci Lett 480: 117-121.
123. Kumar P, Padi SS, Naidu PS, Kumar A, (2006) Effect of resveratrol on 3-nitropropionic acid-induced biochemical and behavioural changes: possible neuroprotective mechanisms. Behav Pharmacol 17: 485-492.
124. Kumar A, Sharma SS, (2010) NF-kappaB inhibitory action of resveratrol: A probable mechanism of neuroprotection in experimental diabetic neuropathy. Biochem Biophys Res Commun 394: 360-365.
125. Kim D, Nguyen MD, Dobbin MM, Fischer A, Sananbenesi F, et al. (2007) SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis. EMBO J 26: 3169-3179.
126. Ranney A, Petro MS, (2009) Resveratrol protects spatial learning in middle-aged C57BL/6 mice from effects of ethanol. Behav Pharmacol 20: 330-336.
127. Oomen CA, Farkas E, Roman V, van der Beek EM, Luiten PG, et al. (2009) Resveratrol preserves cerebrovascular density and cognitive function in aging mice. Front Aging Neurosci 1:4.: 4.
128. Schmatz R, Mazzanti CM, Spanevello R, Stefanello N, Gutierres J, et al. (2009) Ectonucleotidase and acetylcholinesterase activities in synaptosomes from the cerebral cortex of streptozotocin-induced diabetic rats and treated with resveratrol. Brain Res Bull 80: 371-376.
129. Kumar A, Naidu PS, Seghal N, Padi SS, (2007) Neuroprotective effects of resveratrol against intracerebroventricular colchicine-induced cognitive impairment and oxidative stress in rats. Pharmacology 79: 17-26.
130. Jin F, Wu Q, Lu YF, Gong QH, Shi JS, (2008) Neuroprotective effect of resveratrol on 6-OHDA-induced Parkinson's disease in rats. Eur J Pharmacol 600: 78-82.
131. Zhang H, Morgan B, Potter BJ, Ma L, Dellsperger KC, et al. (2010) Resveratrol improves left ventricular diastolic relaxation in type 2 diabetes by inhibiting oxidative/nitrative stress. Am J Physiol Heart Circ Physiol 299: H985-H994.
132. Palsamy P, Subramanian S, (2010) Ameliorative potential of resveratrol on proinflammatory cytokines, hyperglycemia mediated oxidative stress, and pancreatic beta-cell dysfunction in streptozotocin-nicotinamide-induced diabetic rats. J Cell Physiol 224: 423-432.
133. Sharma S, Chopra K, Kulkarni SK, (2007) Effect of insulin and its combination with resveratrol or curcumin in attenuation of diabetic neuropathic pain: participation of nitric oxide and TNF-alpha. Phytother Res 21: 278-283.
134. Larrosa M, Yanez-Gascon MJ, Selma MV, Gonzalez-Sarrias A, Toti S, et al. (2009) Effect of a low dose of dietary resveratrol on colon microbiota, inflammation and tissue damage in a DSS-induced colitis rat model. J Agric Food Chem 57: 2211-2220.
135. Larrosa M, Tome-Carneiro J, Yanez-Gascon MJ, Alcantara D, Selma MV, et al. (2010) Preventive oral treatment with resveratrol pro-prodrugs drastically reduce colon inflammation in rodents. J Med Chem 53: 7365-7376.
136. Sanchez-Fidalgo S, Cardeno A, Villegas I, Talero E, de la Lastra CA, (2010) Dietary supplementation of resveratrol attenuates chronic colonic inflammation in mice. Eur J Pharmacol 633: 78-84.
137. Singh UP, Singh NP, Singh B, Hofseth LJ, Price RL, et al. (2010) Resveratrol (trans-3,5,4′-trihydroxystilbene) induces silent mating type information regulation-1 and down-regulates nuclear transcription factor-kappaB activation to abrogate dextran sulfate sodium-induced colitis. J Pharmacol Exp Ther 332: 829-839.
138. Yao J, Wang JY, Liu L, Li YX, Xun AY, et al. (2010) Anti-oxidant effects of resveratrol on mice with DSS-induced ulcerative colitis. Arch Med Res 41: 288-294.
139. Inanaga K, Ichiki T, Matsuura H, Miyazaki R, Hashimoto T, et al. (2009) Resveratrol attenuates angiotensin II-induced interleukin-6 expression and perivascular fibrosis. Hypertens Res 32: 466-471.
140. Tunali-Akbay T, Sehirli O, Ercan F, Sener G, (2010) Resveratrol protects against methotrexate-induced hepatic injury in rats. J Pharm Pharm Sci 13: 303-310.
141. Csiszar A, Labinskyy N, Podlutsky A, Kaminski PM, Wolin MS, et al. (2008) Vasoprotective effects of resveratrol and SIRT1: attenuation of cigarette smoke-induced oxidative stress and proinflammatory phenotypic alterations. Am J Physiol Heart Circ Physiol 294: H2721-H2735.
142. Sener G, Topaloglu N, Ozer SA, Ercan F, Gedik N, (2007) Resveratrol alleviates bleomycin-induced lung injury in rats. Pulm Pharmacol Ther 20: 642-649.
143. Hong SW, Jung KH, Zheng HM, Lee HS, Suh JK, et al. (2010) The protective effect of resveratrol on dimethylnitrosamine-induced liver fibrosis in rats. Arch Pharm Research 33: 601-609.
144. Sengottuvelan M, Deeptha K, Nalini N, (2009) Influence of dietary resveratrol on early and late molecular markers of 1,2-dimethylhydrazine-induced colon carcinogenesis. Nutrition 25: 1169-1176.
145. Martin AR, Villegas I, Sanchez-Hidalgo M, de la Lastra CA, (2006) The effects of resveratrol, a phytoalexin derived from red wines, on chronic inflammation induced in an experimentally induced colitis model. Br J Pharmacol 147: 873-885.